Neladalkib for Non-Small Cell Lung Cancer
(ALKAZAR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it does mention that you cannot have had prior treatment with ALK inhibitors like alectinib.
Is Neladalkib (Alectinib) safe for humans?
What data supports the effectiveness of the drug Alectinib, which is part of the treatment Neladalkib for Non-Small Cell Lung Cancer?
Research shows that Alectinib, a drug used in Neladalkib, significantly improves progression-free survival (the time during which the cancer does not get worse) and has a good response rate in the brain for patients with ALK-positive non-small-cell lung cancer, especially those who have been treated with other drugs like crizotinib.16789
Who Is on the Research Team?
Viola Zhu, MD, PhD
Principal Investigator
Nuvalent Inc.
Are You a Good Fit for This Trial?
This trial is for patients with advanced ALK-positive NSCLC who haven't had any systemic anticancer treatments (except certain chemotherapies over a year ago). They must have measurable disease, documented ALK rearrangement, and be in good enough health to perform daily activities.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either neladalkib (NVL-655) or alectinib to assess progression-free survival
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Alectinib
- Neladalkib (NVL-655)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nuvalent Inc.
Lead Sponsor